Per Odin

List of Publications by Year
in descending order

86 papers	6,984 citations	109321 35 h-index	60623 81 g-index
88 all docs	88 docs citations	88 times ranked	4703 citing authors

#	Article	IF	Citations
1	International multicenter pilot study of the first comprehensive selfâ€completed nonmotor symptoms questionnaire for Parkinson's disease: The NMSQuest study. Movement Disorders, 2006, 21, 916-923.	3.9	865
2	The metric properties of a novel nonâ€motor symptoms scale for Parkinson's disease: Results from an international pilot study. Movement Disorders, 2007, 22, 1901-1911.	3.9	838
3	Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurology, The, 2014, 13, 141-149.	10.2	547
4	The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire. Movement Disorders, 2010, 25, 704-709.	3.9	342
5	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology, 1997, 42, 95-107.	5.3	331
6	Summary of the recommendations of the <scp>EFNS</scp>/<scp>MDS</scp>â€<scp>ES</scp> review on therapeutic management of <scp>P</scp>arkinson's disease. European Journal of Neurology, 2013, 20, 5-15.	3.3	290
7	Nonmotor fluctuations in Parkinson disease. Neurology, 2013, 80, 800-809.	1.1	284
8	Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders, 2009, 24, 1468-1474.	3.9	233
9	Gender-related differences in the burden of non-motor symptoms in Parkinsonâ€™s disease. Journal of Neurology, 2012, 259, 1639-1647.	3.6	211
10	Euro<scp>I</scp>nf: <scp>A</scp><scp>M</scp>ulticenter <scp>C</scp>omparative <scp>O</scp>bservational <scp>S</scp>tudy of <scp>A</scp>pomorphine and <scp>L</scp>evodopa <scp>I</scp>nfusion in <scp>P</scp>arkinson's <scp>D</scp>isease. Movement Disorders, 2015, 30, 510-516.	3.9	203
11	Levodopaâ€carbidopa intestinal gel in advanced Parkinson's disease: Final 12â€month, openâ€label results. Movement Disorders, 2015, 30, 500-509.	3.9	199
12	Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. Journal of Neurology, Neurosurgery and Psychiatry, 1998, 65, 709-716.	1.9	166
13	Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson's disease: Consensus from an international survey and discussion program. Parkinsonism and Related Disorders, 2015, 21, 1133-1144.	2.2	156
14	Levodopa-carbidopa intestinal gel in advanced Parkinson's: Final results of the GLORIA registry. Parkinsonism and Related Disorders, 2017, 45, 13-20.	2.2	149
15	Selecting deep brain stimulation or infusion therapies in advanced Parkinsonâ€™s disease: an evidence-based review. Journal of Neurology, 2013, 260, 2701-2714.	3.6	128
16	EuroInf 2: Subthalamic stimulation, apomorphine, and levodopa infusion in Parkinson's disease. Movement Disorders, 2019, 34, 353-365.	3.9	126
17	Chronic Subcutaneous Infusion Therapy with Apomorphine in Advanced Parkinson's Disease Compared to Conventional Therapy: A Real Life Study of Non Motor Effect. Journal of Parkinson's Disease, 2011, 1, 197-203.	2.8	107
18	Continuous Jejunal Levodopa Infusion in Patients With Advanced Parkinson Disease. Clinical Neuropharmacology, 2008, 31, 151-166.	0.7	105

#	Article	IF	Citations
19	Levodopaâ€“carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism and Related Disorders, 2013, 19, 339-345.	2.2	95
20	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS ONE, 2013, 8, e57221.	2.5	95
21	The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: A simple grading system. Parkinsonism and Related Disorders, 2015, 21, 287-291.	2.2	93
22	Integrated safety of levodopaâ€carbidopa intestinal gel from prospective clinical trials. Movement Disorders, 2016, 31, 538-546.	3.9	91
23	Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The <scp>COVID</scp>â€19 Experience. Movement Disorders Clinical Practice, 2020, 7, 361-372.	1.5	91
24	Levodopaâ€“Carbidopa Intestinal Gel in Patients with Parkinsonâ€™s Disease: A Systematic Review. CNS Drugs, 2016, 30, 381-404.	5.9	81
25	Effect and safety of duodenal levodopa infusion in advanced Parkinsonâ€™s disease: a retrospective multicenter outcome assessment in patient routine care. Journal of Neural Transmission, 2013, 120, 1553-1558.	2.8	59
26	Intrajejunal Levodopa Versus Conventional Therapy in Parkinson Disease. Clinical Neuropharmacology, 2012, 35, 205-207.	0.7	51
27	Parkinson's Disease and <scp>Postâ€“COVID</scp>â€19 Syndrome: The Parkinson's <scp>Longâ€COVID</scp> Spectrum. Movement Disorders, 2021, 36, 1287-1289.	3.9	51
28	The Nonâ€Motor Symptoms Scale in Parkinsonâ€™s disease: Validation and use. Acta Neurologica Scandinavica, 2021, 143, 3-12.	2.1	49
29	A Consensus Set of Outcomes for Parkinsonâ€™s Disease from the International Consortium for Health Outcomes Measurement. Journal of Parkinson's Disease, 2017, 7, 533-543.	2.8	45
30	Non-oral dopaminergic therapies for Parkinsonâ€™s disease: current treatments and the future. Npj Parkinson's Disease, 2016, 2, 16023.	5.3	43
31	Algorithms for the treatment of motor problems in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 136, 378-385.	2.1	43
32	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of Aging, 2015, 36, 1736-1742.	3.1	42
33	The Long-Term Impact of Levodopa/Carbidopa Intestinal Gel on â€˜Offâ€™-time in Patients with Advanced Parkinsonâ€™s Disease: A Systematic Review. Advances in Therapy, 2021, 38, 2854-2890.	2.9	41
34	Factors associated with life satisfaction in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 136, 64-71.	2.1	38
35	Cost-effectiveness of continuous subcutaneous apomorphine in the treatment of Parkinsonâ€™s disease in the UK and Germany. Journal of Medical Economics, 2015, 18, 155-165.	2.1	37
36	Continuous Drug Delivery Aiming Continuous Dopaminergic Stimulation in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, S65-S72.	2.8	32

#	Article	IF	Citations
37	Device-Aided Treatment Strategies in Advanced Parkinson's Disease. International Review of Neurobiology, 2017, 132, 453-474.	2.0	29
38	Levodopa Effect and Motor Function in Late Stage Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 59-70.	2.8	28
39	Factors Contributing to Perceived Walking Difficulties in People with Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2017, 7, 397-407.	2.8	27
40	Study protocol: Care of Late-Stage Parkinsonism (CLaSP): a longitudinal cohort study. BMC Neurology, 2018, 18, 185.	1.8	27
41	Digital health technology for non-motor symptoms in people with Parkinson's disease: Futile or future?. Parkinsonism and Related Disorders, 2021, 89, 186-194.	2.2	26
42	The late stage of Parkinson's â€“results of a large multinational study on motor and non-motor complications. Parkinsonism and Related Disorders, 2020, 75, 91-96.	2.2	25
43	The Prevalence and Determinants of Neuropsychiatric Symptoms in <scp>Lateâ€Stage</scp> Parkinsonism. Movement Disorders Clinical Practice, 2020, 7, 531-542.	1.5	24
44	Validation and clinical value of the MANAGE-PD tool: A clinician-reported tool to identify Parkinson's disease patients inadequately controlled on oral medications. Parkinsonism and Related Disorders, 2021, 92, 59-66.	2.2	23
45	Personalised Advanced Therapies in Parkinsonâ€™s Disease: The Role of Non-Motor Symptoms Profile. Journal of Personalized Medicine, 2021, 11, 773.	2.5	20
46	Dopaminergic Effect on Non-Motor Symptoms in Late Stage Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, 409-420.	2.8	18
47	Caregiver Burden in Late-Stage Parkinsonism and Its Associations. Journal of Geriatric Psychiatry and Neurology, 2022, 35, 110-120.	2.3	18
48	Characteristics of Patients with Late-Stage Parkinsonism Who are Nursing Home Residents Compared with those Living at Home. Journal of the American Medical Directors Association, 2021, 22, 440-445.e2.	2.5	18
49	Effects of safinamide on pain in patients with fluctuating Parkinson's disease. Brain and Behavior, 2021, 11, e2336.	2.2	18
50	Impact of age at onset on symptom profiles, treatment characteristics and health-related quality of life in Parkinsonâ€™s disease. Scientific Reports, 2022, 12, 526.	3.3	18
51	Factors Associated with Healthâ€Related Quality of Life in Lateâ€Stage Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 563-570.	1.5	16
52	Mobility device use in people with Parkinson's disease: A 3-year follow-up study. Acta Neurologica Scandinavica, 2018, 138, 70-77.	2.1	14
53	Continuous dopaminergic stimulation therapy for Parkinson's disease â€“ recent advances. Current Opinion in Neurology, 2016, 29, 474-479.	3.6	13
54	Perspectives on Care for Late-Stage Parkinsonâ€™s Disease. Parkinson's Disease, 2021, 2021, 1-11.	1.1	13

#	Article	IF	Citations
55	Caregiver Burden and Quality of Life in Late Stage Parkinsonâ€™s Disease. Brain Sciences, 2022, 12, 111.	2.3	13
56	Low prevalence of known pathogenic mutations in dominant PD genes: A Swedish multicenter study. Parkinsonism and Related Disorders, 2019, 66, 158-165.	2.2	12
57	A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia. Movement Disorders, 2020, 35, 1046-1054.	3.9	12
58	Does the 5â€“2-1 criteria identify patients with advanced Parkinson's disease? Real-world screening accuracy and burden of 5â€“2-1-positive patients in 7 countries. BMC Neurology, 2022, 22, 35.	1.8	12
59	Cost-Effectiveness of Device-Aided Therapies in Parkinsonâ€™s Disease: A Structured Review. Journal of Parkinson's Disease, 2021, 11, 475-489.	2.8	11
60	Parkinsonâ€™s disease in Swedenâ€”resource use and costs by severity. Acta Neurologica Scandinavica, 2021, 144, 592-599.	2.1	11
61	Nonâ€oral Continuous Drug Delivery Techniques in Parkinson's Disease: For Whom, When, and How?. Movement Disorders Clinical Practice, 2016, 3, 221-229.	1.5	10
62	Workforce unavailability in Parkinson's disease. Acta Neurologica Scandinavica, 2017, 135, 332-338.	2.1	10
63	Can suitable candidates for levodopa/carbidopa intestinal gel therapy be identified using current evidence?. ENeurologicalSci, 2017, 8, 44-53.	1.3	10
64	Disease stage dependency of motor and non-motor fluctuations in Parkinsonâ€™s disease. Journal of Neural Transmission, 2019, 126, 841-851.	2.8	9
65	Validation of the PD home diary for assessment of motor fluctuations in advanced Parkinsonâ€™s disease. Npj Parkinson's Disease, 2022, 8, .	5.3	9
66	Satisfaction with Care in Late Stage Parkinsonâ€™s Disease. Parkinson's Disease, 2019, 2019, 1-10.	1.1	8
67	Opicapone versus placebo in the treatment of Parkinsonâ€™s disease patients with end-of-dose motor fluctuation-associated pain: rationale and design of the randomised, double-blind OCEAN (OpiCapone) Tj ETQq1 1 0.784314 rgBT /Ov		
68	Swedish guidelines for deviceâ€aided therapies in Parkinson's disease â€”Economic evaluation and implementation. Acta Neurologica Scandinavica, 2021, 144, 170-178.	2.1	7
69	Advance Care Planning and Care Coordination for People With Parkinson's Disease and Their Family Caregiversâ€”Study Protocol for a Multicentre, Randomized Controlled Trial. Frontiers in Neurology, 2021, 12, 673893.	2.4	7
70	Safinamide in the treatment pathway of Parkinsonâ€™s Disease: a European Delphi Consensus. Npj Parkinson's Disease, 2022, 8, 17.	5.3	7
71	Infusional Therapies, Continuous Dopaminergic Stimulation, and Nonmotor Symptoms. International Review of Neurobiology, 2017, 134, 1019-1044.	2.0	6
72	Optimizing Treatment in Undertreated Late-Stage Parkinsonism: A Pragmatic Randomized Trial. Journal of Parkinson's Disease, 2020, 10, 1171-1184.	2.8	6

#	Article	IF	Citations
73	Longitudinal prediction of falls and near falls frequencies in Parkinsonâ€™s disease: a prospective cohort study. Journal of Neurology, 2021, 268, 997-1005.	3.6	6
74	Psychometric Properties of Clinical Indicators for Identification and Management of Advanced Parkinsonâ€™s Disease: Real-World Evidence From G7 Countries. Neurology and Therapy, 2022, 11, 303-318.	3.2	6
75	Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy. Acta Neurologica Scandinavica, 2018, 138, 78-84.	2.1	5
76	Close relationships in ParkinsonÂ´s disease patients with deviceâ€aided therapy. Brain and Behavior, 2021, 11, e02102.	2.2	5
77	Levodopa infusion in Parkinson's disease: Individual quality of life. Acta Neurologica Scandinavica, 2020, 142, 248-254.	2.1	4
78	Continuous Intra-intestinal Infusion of Levodopa/Carbidopa in Advanced Parkinson's Disease. European Neurological Review, 2007, , 45.	0.5	4
79	Quality of life and resource utilizationâ€Swedish data from the Care of Lateâ€Stage Parkinsonism (CLaSP) study. Acta Neurologica Scandinavica, 2022, 145, 743-752.	2.1	4
80	Lack of Accredited Clinical Training in Movement Disorders in Europe, Egypt, and Tunisia. Journal of Parkinson's Disease, 2020, 10, 1833-1843.	2.8	3
81	Authorsâ€™ Reply to Lambarth: â€œLevodopa-Carbidopa Intestinal Gel in Patients with Parkinsonâ€™s Disease: A Systematic Reviewâ€• CNS Drugs, 2016, 30, 1009-1010.	5.9	1
82	Patient Utilities in Health States Based on Hoehn and Yahr and Off-Time in Parkinsonâ€™s Disease: A Swedish Register-Based Study in 1823 Observations. Pharmacoeconomics, 2021, 39, 1141-1149.	3.3	1
83	Clinical Usefulness of Retropulsion Tests in Persons with Mild to Moderate Parkinsonâ€™s Disease. International Journal of Environmental Research and Public Health, 2021, 18, 12325.	2.6	1
84	Everyday Occupations and Other Factors in Relation to Mental Well-Being among Persons with Advanced Parkinsonâ€™s Disease. Occupational Therapy in Health Care, 2020, 34, 1-18.	0.3	0
85	Gastrointestinal dysfunction in Parkinson's disease. International Review of Movement Disorders, 2021, 1, 179-208.	0.1	0
86	Diagnostic work up: Laboratory and biomarkers. International Review of Neurobiology, 2022, 162, 53-96.	2.0	0